A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

Stopped Company decision to discontinue the study, not due to any safety or efficacy concerns

Conditions

• Prostatic Neoplasms

Interventions

• DRUG: Docetaxel
• DRUG: Leuprolide
• DRUG: Bicalutamide

Sponsor

Sanofi